About Nevro
Nevro is a Healthcare company based in Menlo Park (United States) founded in 2006, and was acquired by Globus Medical in February 2025. Provider of high-frequency spinal cord stimulation implants. Nevro has raised $154.1 million across 8 funding rounds from investors including Medtronic, Globus Medical and CRG. The company has 1,215 employees. Nevro has completed 1 acquisition, including VYRSA Technologies. Its website nevro.com draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is NEVRO CORP. Its competitors include Vertos Medical, Paradigm Spine and ATEC Spine; 2 of its 3 listed competitors have raised funding.
Company details
Nevro was founded in 2006 and is based in Menlo Park, United States. The company operates within the medical device sector, specializing in neuromodulation for pain management. Spinal cord stimulation therapies are delivered via the Senza SCS system, which employs high-frequency technology. Development and distribution of these implants occur primarily in the U.S., targeting chronic pain conditions.
- Headquarters Menlo Park, United States
- Employees 1,215
- Stage Acquired
- SectorsHealthcare
- Website nevro.com
- Social LinkedIn X Facebook
- Acquired by Globus Medical (Feb 2025)
- Legal Name Nevro Corp
- Annual Revenue$353.08 M (USD)502as on Mar 31, 2024
- Net Profit-$113.44 M (USD)-23as on Mar 31, 2024
- EBITDA-$126.23 M (USD)-27as on Mar 31, 2024
- Total Equity Funding$154.1M (USD)
in 8 rounds
- Latest Funding Round$189.75M (USD), Post-IPO
Apr 2020
- InvestorsMedtronic
& 11 more
- Employee Count1,215
- Investments & Acquisitions
- Acquired byGlobus Medical
(Feb 2025)
Funding Insights of Nevro
Nevro has successfully raised a total of $154.1M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $189.75 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $154.1M
- Total Rounds 8
- Last Round Post-IPO — $189.75M
- First Round $5.5M
(Dec 2006)
- Investors Count 11
All 8 funding rounds of Nevro with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $189.75M | Post-IPO | – | – | – |
| Jun 2016 | $150M | Post-IPO | – | – | – |
| Dec 2014 | $20M | Debt – Conventional | – | – | |
| Mar 2013 | $48M | Series C | – | New Enterprise Associates, Medtronic | |
| Jul 2011 | $58.6M | Series B | – | Johnson & Johnson Innovation – JJDC | |
| Apr 2010 | $20M | Series A | – | – | – |
| Oct 2008 | $22M | Series A | – | Accuitive Medical Ventures, Aberdare Ventures | – |
| Dec 2006 | $5.5M | Seed | – | Aberdare Ventures, Bay City Capital | – |
12 investors in total: 12 institutional.
Investors in Nevro
Nevro has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Medtronic, Globus Medical and CRG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Early-stage US healthcare investments are made by Accuitive Medical Ventures. | amvpartners.com | Duluth, United States | ||
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
Life science & tech focused VC firm investing in companies in the US | threearchpartners.com | San Mateo, United States | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | aberdare.com | San Francisco, United States | ||
Medical equipment for treating over 30 chronic diseases is developed. | 1949 | medtronic.com | Minneapolis, United States | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com |
Investor details for Nevro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Nevro
468 people are tracked at Nevro (127 in leadership, 10 in board & advisors, 331 in team); the tracked headcount is 1,215.
| Name | Role | Group |
|---|---|---|
Yeqing Cao | Director, Product Development | Leadership |
Dan Cummings | Zone Director - East | Leadership |
Mark Fromhold | Director, Product Development | Leadership |
Craig Blinman | Director, Operations APAC | Leadership |
John J. Mulcahy | Chief Commercial Officer, President Of Orthopedics | Leadership |
Mark Etheridge | Area Sales Director | Leadership |
Jeremy Tuten | Vice President Of Sales | Leadership |
Lisandra Abreu-Kelsey | Senior Talent Acquisition Partner - EMEA | Leadership |
Alessio Lentati | Country Sales Director | Leadership |
Jordan Smith | Southeast Area Director - Trauma | Leadership |
Suzanne Dinatale | Vice President Of Biologics-west | Leadership |
Larry Brickman | Area Director/sales Manager, NYC Empire Region | Leadership |
Andrew Fowler | Vice President Of US Sales - Pacific Zone | Leadership |
J.j. McIntyre | Area Director- Central US | Leadership |
Ryan Reynolds | Area Director | Leadership |
Jeff Blumenthal | Zone Vice President | Leadership |
Daniel Paul | Senior Vice President, Global Quality, Regulatory And Information Technology | Leadership |
Christy Mace | Director of Product Development | Leadership |
Keith Pfeil | President & CEO | Leadership |
Lynn Kennelly | Director Talent Acquisition | Leadership |
448 more people are available in the full profile.
Complete people profiles for Nevro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nevro
Nevro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include VYRSA Technologies.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Sacroiliac joint fusion technologies are specialized in by VYRSA Technologies. | vyrsatech.com | King Of Prussia, United States | 2021 | Nov 2023 | $40M |
Complete acquisition details for Nevro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Nevro
6 dated milestones of Nevro across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Nevro is founded.
- Funding First funding round of $5.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $189.8M.
- Acquisition Acquires VYRSA Technologies.
- Exit Acquired by Globus Medical.
Competitors of Nevro
Nevro has 3 listed competitors in our database, 2 of them funded. They include Vertos Medical, Paradigm Spine and ATEC Spine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vertosmed.com | 2005 | Aliso Viejo, United States | $177.75M | 140 | Minimally invasive treatments for lumbar spinal stenosis are developed. | |
| paradigmspine.com | 2005 | New York, United States | $142.15M | 43 | Stabilization devices for healthcare are manufactured by the company. | |
| atecspine.com | 1990 | San Diego, United States | 839 | Treatment solutions for spine disorders are developed. |
Detailed competitors of Nevro
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Nevro
The website of Nevro (nevro.com) receives about 11.4K visits a month.
- Monthly visits11.4K
▲ 26.1% vs previous month
Websites whose visitors overlap most with Nevro. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| medicaldevice-network.com | 100% | #456,669 | View details | ||
nevrohfx.com | nevrohfx.com | 82% | #273,740 | – | |
tpoftampa.com | tpoftampa.com | 58% | #1,255,113 | – | |
| uhms.org | 53% | 51.4K | #590,967 | View details |
Top companies in Orthopedics
3 companies that operate in the same segment as Nevro (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nevro
Complete news archive for Nevro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nevro
Nevro was founded in 2006.
Nevro is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Nevro is a funded company, having raised a total of $154.1M across 8 funding rounds to date. The company's 1st funding round was a Seed of $5.5M, raised on Dec 2006.
Nevro has 1,215 employees.
Annual revenue of Nevro is $353.08M as on Mar 31, 2024.
Nevro was founded in 2006 and is based in Menlo Park, United States. The company operates within the medical device sector, specializing in neuromodulation for pain management. Spinal cord stimulation therapies are delivered via the Senza SCS system, which employs high-frequency technology. Development and distribution of these implants occur primarily in the U.S., targeting chronic pain conditions.
Nevro's top competitors include Paradigm Spine, ATEC Spine and Vertos Medical.
Nevro has made 1 acquisition, including VYRSA Technologies.
Nevro has 12 investors. Key investors include Medtronic, Globus Medical, CRG, NEA, and Accuitive Medical Ventures.
Nevro operates through Nevro Corp.
Yes. Nevro was acquired by Globus Medical in February 2025.